Prolacta Bioscience Announces In-Vitro Study Results on Effects of Human Milk Fortifiers for Premature Infants  
2/12/2008 8:43:51 AM

MONROVIA, Calif.--(BUSINESS WIRE)--Prolacta Bioscience, the first and only company to offer human milk fortifier made from 100% human breast milk for premature and critically ill infants in the neonatal intensive care unit (NICU), has announced the results of a recent published research paper by lead author Dr. Gary Chan from the University of Utah. The experiment, published in Breastfeeding Medicine, studied the antibacterial actions of human milk by comparing the effects of human breast milk-derived fortifier when mixed with breast milk, versus those of a powdered bovine-based fortifier on the same milk.